Peripheral blood stem cell mobilization: New regimens, new cells, where do we stand

Current Opinion in Hematology

Volumn 15, Issue 4, 2008, Pages 285-292

  Pelus, Louis M ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Hematopoietic transplantation; Peripheral blood stem cell mobilization; Stem cells

Indexed keywords

ANGIOPOIETIN 1; ANTIBODY; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE; CHEMOKINE RECEPTOR AGONIST; CTCE 0021; CTCE 0214; CYCLOPHOSPHAMIDE; DEXTRAN SULFATE; ERYTHROPOIETIN; FLUOROURACIL; FUCOIDIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 3; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR BETA; PARATHYROID HORMONE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA; THROMBOPOIETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4 ANTIBODY; ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR;

CELL POPULATION; CLINICAL TRIAL; DRUG POTENTIATION; GOLD STANDARD; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; ANIMAL; DRUG ANTAGONISM; METHODOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

ANIMALS; CHEMOKINES, CXC; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, CXCR;

EID: 47149117791     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328302f43a     Document Type: Review

References (130)

1. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18:3964-3972.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic transplants of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230-247.
3. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. J Cell Biol 1988; 106:2139-2151.
4. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007; 213:341-347.
5. McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171:293-294.
6. Kurnick JE, Robison WA. Colony growth of human peripheral white blood cells in vitro. Blood 1971; 37:136-141.
7. Chervenick PA, Boggs DR. In vitro growth of granulocytic and mononuclear cell colonies from blood of normal individuals. Blood 1971; 37:131-135.
8. Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hemato-poietic stem cell transplantation in Europe. Blood 2002; 100:2374-2386.
9. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/ progenitor cell mobilization. Blood 2004; 103:1580-1585.
10. Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003; 122:360-375.
11. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002; 9:183-189.
12. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89:2233-2258.
13. Goldman JM, Horowitz MM. The international bone marrow transplant registry. Int J Hematol 2002; 76 (Suppl 1):393-397.
14. Ringden O, Remberger M, Runde V, et al. Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. Bone Marrow Transplant 2000; 25 (Suppl 2):S6-S8.
15. Benito AI, Diaz MA, Gonzalez-Vicent M, et al. Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant 2004; 33:675-690.
16. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recom-binant granulocyte stimulating factor. Blood 1993; 81:3158-3163.
17. Blume KG, Thomas ED. A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:1-12.
18. Kennedy J. Peripheral blood progenitor cell mobilization: a clinical review. Pharmacotherapy 1998; 18:3-8.
19. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-1929.
20. Heldal D, Tjonnfjord G, Brinch L, et al. A randomized study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25:1129-1136.
21. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175-181.
22. Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16:1547-1553.
23. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186-1193.
24. Reisner Y, Martelli MF. Transplantation tolerance induced by 'mega dose' CD34p cell transplants. Exp Hematol 2000; 28:119-127.
25. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353:555.
26. Balaguer H, Galmes A, Ventayol G, et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44:1260-1261.
27. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34p peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17:869-875.
28. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94:1465-1470.
29. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31:839-845.
30. Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after nonmyeloablative conditioning. Br J Haematol 2005; 128:659-667.
31. Heimfeld S. Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? Leukemia 2003; 17:856-858.
32. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89:4226-4235.
33. BaronF, Maris MB, Storer BE, et al. High doses of transplanted CD34p cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19:822-828.
34. Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26:471-481.
35. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of 'hard to mobilize' lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39:509-519.
36. Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44:777-784.
37. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002; 9:190-198.
38. Carral A, de la RJ, Martin G, et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and nonmyeloid malignancies. Leuk Res 2003; 27:5-12.
39. Keating S, Suciu S, de Witte T, et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003; 17:60-67.
40. Mele A, Leopardi G, Sparaventi G, et al. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. Eur J Haematol 2005; 74:277-281.
41. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34p cells in normal donors treated with filgrastim. Transfusion 1997; 37:507-512.
42. Holm M. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 1998; 7:111 -113.
43. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85:1666-1672.
44. Ng-Cashin J, Shen T. Mobilization of autologous peripheral blood hematopoietic cells for support of high-dose cancer therapy. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation, 3rd ed. Malden: Blackwell Publishing Ltd; 2004. pp. 576-587.
45. Schmitz N. Peripheral blood hematopoietic cells for allogeneic transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation, 3rd ed. Malden: Blackwell Publishing Ltd; 2004. pp. 588-598.
46. Croop JM, Cooper R, Fernandez C, et al. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood 2001; 98:2917-2921.
47. Sloand EM, Read EJ, Scheinberg P, et al. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. Transfusion 2007; 47:1250-1253.
48. Roberts AW, DeLuca E, Begley CG, et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13:512-516.
49. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86:4437-4445.
50. de la RJ, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42:4-9.
51. Bachar-Lustig E, Li HW, Gur H, et al. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(-) bone marrow progenitor cells: synergism with nonalloreactive (host x donor)F(1)T cells. Blood 1999; 94:3212-3221.
52. Fruehauf S, Klaus J, Huesing J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39:743-750.
53. Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46:180-185.
54. Nosari A, Cairoli R, Ciapanna D, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006; 38:413-416.
55. Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93:405-412.
56. Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90:225-231.
57. Hosing C, Qazilbash MH, Kebriaei P, et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133:533-537.
58. Kuendgen A, FenkR, Bruns I, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38:69-70.
59. Kroschinsky F, Holig K, Poppe-ThiedeK, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90:1665-1671
60. Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46:747-757.
61. Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93:2491 -2501.
62. Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003; 9:405-413.
63. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85:275-282.
64. Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF +GM-CSF vs. G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997; 20:921 -930.
65. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998; 91:100-110.
66. Mohle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91:4523-4530.
67. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16:1992-2003.
68. Lord BI, Woolford LB, Wood LM, et al. Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 1995; 85:3412-3415.
69. Broxmeyer HE, Cooper S, Hangoc G, et al. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med 1999; 189:1987-1992.
70. Pelus LM, Bian H, King AG, et al. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRO-betaT/CXCL2delta4. Blood 2004; 103:110-119.
71. Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a betterhematopoietic graft. Leukemia 2008; 22:466-473.
72. King AG, Horowitz D, Levin R, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood 2001; 97:1534-1542.
73. Pelus LM, Horowitz D, Cooper SC, et al. Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol 2002; 43:257-275.
74. Fibbe WE, Pruijt JF, Velders GA, et al. Biology of IL-8-induced stem cell mobilization. Ann N Y Acad Sci 1999; 872:71 -82.
75. Pelus LM, Broxmeyer HE. Chemokine axes in hematopoietic stem cell mobilization. In: Neote K, Letts GL, Moser B, editors. Chemokine biology-basic research and clinical application. Vol II. Pathophysiology of chemokines. Basel: Birkhauser Verlag AG; 2007. pp. 125-144.
76. Merzouk A, Wong D, Salari H, et al. Rational design of chemokine SDF-1 analogs with agonist activity for the CXCR4 receptor and the capacity to rapidly mobilize PMN and hematopoietic progenitor cells in mice. Lett Drug Design Discov 2004; 1:126-134.
77. Pelus LM, Bian H, Fukuda S, et al. TheCXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol 2005; 33:295-307.
78. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201:1307-1318.
79. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:2728-2730.
80. Shen H, Cheng T, Olszak I, et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001; 166:5027-5033.
81. Burroughs L, MielcarekM, Little MT, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005; 106:4002-4008.
82. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107:3772-3778.
83. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1095-1102.
84. Grignani G, Perissinotto E, Cavalloni G, et al. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J Clin Oncol 2005; 23:3871 -3872.
85. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45:295-300.
86. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867-1874.
87. Cashen A, Calandra G, Macfarland R, et al. A mobilizing regimen of AMD3100 and G-CSF increases stem cell collection in patients with Hodgkin's disease, and PK is similar to that of non-cancer patients. Blood 2006; 108:869a.
88. DiPersio JF, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Perixafor) +G-CSF vs. G-CSF + placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007; 110:137a.
89. Di Persio JF, Micallef I, Stiff P, et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Perixafor) + G-CSF vs. placebo + G-CSF in non-Hodgkins lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007; 110:185a.
90. Micallef I, Stiff P, DiPersio JF, et al. Successful stem cell mobilization rescue byAMD3100 (Perixafor) + G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study. Blood 2007; 110:185a-186a.
91. Gothot A, van der Loo JC, Clapp DW, et al. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in nonobese diabetic/severe combined immune-deficient mice. Blood 1998; 92:2641 -2649.
92. Ramshaw HS, Rao SS, Crittenden RB, et al. Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. Blood 1995; 86:924-929.
93. Schuchert MJ, Wright RD, Colson YL. Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8+ bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nat Med 2000; 6:904-909.
94. Gandy KL, Domen J, Aguila H, et al. CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 1999; 11:579-590.
95. Christopherson KW, Hangoc G, Mantel CR, et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305:1000-1003.
96. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283:845-848.
97. Hassan HT, Zeller W, Stockschlader M, et al. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection. Stem Cells 1996; 14:419-429.
98. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-596.
99. Verfaillie CM, Almeida-PoradaG, Wissink S, et al. Kinetics of engraftment of CD34(-) and CD34(+) cells from mobilized blood differs from that of CD34(-) and CD34(+) cells from bone marrow. Exp Hematol 2000; 28:1071-1079.
100. Bonig H, Priestley GV, Oehler V, et al. Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol 2007; 35:326-334.
101. Fukuda S, Bian H, King AG, et al. The chemokine GROβ mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007; 110:860-869.
102. Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006; 34:1052-1059.
103. Hess DA, Bonde J, Craft TP, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007; 13:398-411.
104. Devine SM, Andritsos L, Todt L, et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood 2006; 106:299a.
105. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193:1005-1014.
106. Hu J, Takatoku M, Sellers SE, et al. Analysis of origin and optimization of expansion and transduction of circulating peripheral blood endothelial progenitor cells in the rhesus macaque model. Hum Gene Ther 2002; 13:2041 -2050.
107. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98:10344-10349.
108. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9:702-712.
109. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005; 106:1525-1531.
110. Rehman J, Li J, Orschell CM, et al. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107:1164-1169.
111. De Palma M, Venneri MA, RocaC, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9:789-795.
112. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295:1003-1010.
113. Ripa RS, Jorgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113:1983-1992.
114. Stroncek DF, Clay ME, Herr G, et al. The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfus Med 1997; 7:19-24.
115. Kang HJ, Kim HS, Koo BK, et al. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am Heart J 2007; 153:237-238.
116. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007; 115:3165-3172.
117. Kawamura A, HorieT,TsudaI, et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006; 9:226-233.
118. + mobilized by G-CSF in a patient with critical limb ischemia.
119. Shepherd RM, Capoccia BJ, Devine SM, et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006; 108:3662-3667.
120. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109:235-242.
121. Bieback K, Kern S, Kluter H, et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22:625-634.
122. Lee OK, KuoTK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103:1669-1675.
123. Fernandez M, Simon V, Herrera G, et al. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant 1997; 20:265-271.
124. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000; 2:477-488.
125. Kuznetsov SA, Mankani MH,GronthosS, et al. Circulating skeletal stem cells. J Cell Biol 2001; 153:1133-1140.
126. Kassis I, Zangi L, Rivkin R, et al. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant 2006; 37:967-976.
127. Lazarus HM, Haynesworth SE, Gerson SL, et al. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997; 6:447-455.
128. Wexler SA, Donaldson C, Denning-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003; 121:368-374.
129. Rochefort GY, Delorme B, Lopez A, et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006; 24:2202-2208.
130. Levesque JP, Winkler IG, Larsen SR, et al. Mobilization of bone marrow-derived progenitors. Handb Exp Pharmacol 2007; 3-36.